伐昔洛韦对频发性生殖器疱疹的抑制疗法

目的研究伐昔洛韦抗病毒抑制疗法治疗频发性生殖器疱疹的临床效果。方法将120例频发性生殖器疱疹患者(复发次数>6次/年)采用数字表法随机分成4组,Ⅰ组:阿昔洛韦400 mg,每d 2次6个月;Ⅱ组:伐昔洛韦500 mg,每d 1次6个月;Ⅲ组:伐昔洛韦500 mg,每d 2次3个月;Ⅳ组:伐昔洛韦500 mg,每d 2次3个月,500 mg,每d 1次3个月。对患者复发情况进行观察,并检测患者单纯疱疹病毒2型(herpes simplex virus 2,HSV-2)DNA病毒载量的变化。结果与治疗前相比,4种治疗方案均能明显减少患者疱疹的复发次数,其中Ⅳ组减少复发次数与其他3组比较差异均有统计学意义(P均<0.05)。伐昔洛韦500 mg,每d 2次能有效抑制病毒复制,后续的减量抑制疗法可以进一步抑制病毒复制。结论伐昔洛韦能有效预防患者频发性生殖器疱疹复发,并且能够有效抑制病毒复制。

Effect of valaciclovir for preventing the recurrence of recurrent genital herpes

Objective To study the clinical effects of valacyclovir administered as suppressive therapy for patients with recurrent genital herpes(GH). Methods A total of 120 patients were randomly divided into four groups: patients in group 1 were treated with 400 mg aciclovir, Bid for 6 months; those in group 2 were treated with 500 mg valaciclovir, qd for 6 months; those in group 3, were treated with 500 mg valaciclovir, Bid for 3 months; and those in group 4, were treated with 500 mg valaciclovir, Bid for 3 months, and then with 500 mg valaciclovir, qd for 3 months. The patients were observed for the recurrence of GH after treatment and were followed up, and the viral load of HSV-2 DNA was monitored. Results Compared with pre-therapy, the recurrence of GH was significantly reduced in all the 4 groups, especially in group 4. Administration of 500 mg valaciclovir, Bid, could inhibit the replication of HSV-2 efficiently, and the subsequent reduced dose treatment additionally inhibited the replication of HSV-2. Conclusion Valaciclovir can not only reduce the recurrence of GH, but also efficiently inhibit replication of HSV-2.